US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.
You may also be interested in...
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.